Atlassian uses cookies to improve your browsing experience, perform analytics and research, and conduct advertising. Accept all cookies to indicate that you agree to our use of cookies on your device. Atlassian cookies and tracking notice, (opens new window)
Welcome to the PHUSE Advance Hub

WORKING GROUPS
Results will update as you type.
  • Working Groups
    • Data Transparency
    • Data Visualisation & Open Source Technology
    • Emerging Trends & Innovation
    • Nonclinical Topics
    • Optimizing the Use of Data Standards
      • Bioresearch Monitoring (BIMO) Frequently Asked Questions Forum
      • Building a Better MDR
      • Clinical Integrated Study Data & Analysis Data Reviewer's Guide
      • Electronic Data Submission in Japan
      • Management of ODS Regulatory Referenced Deliverables
      • SDTM ADaM Implementation FAQ
        • Data Submission
        • SDTM/ADaM Harmonisation
        • SDTM/ADaM IG Nuances
        • Imputing Partial Dates
        • Trial, Design, Domain
        • Validation/Conformance Rules
    • pharmaverse
    • Real World Evidence
    • Risk Based Quality Management
    • Safety Analytics
  • Hot Topics
  • Useful Information
  • Deliverables
  • Working Groups Events
  • Working Groups Report – Q3 2025
  • Working Groups Archive
  • Working Groups Events Archive

    You‘re viewing this with anonymous access, so some content might be blocked.
    /
    SDTM ADaM Implementation FAQ

      SDTM ADaM Implementation FAQ

      Oct 01, 2025

      Project Scope 

      The Standards Implementation Nuances sessions at the March North America 2016 CSS and June EU 2016 CSS surfaced various common challenges amongst SDTM and ADaM implementers and consumers. In addition, there were many questions discussed related to data submissions requirements by various regulatory agencies around the world (e.g. FDA, PMDA, NMPA). It became very clear that the Industry is in need of a forum and subsequent knowledge-base (FAQ) to address these challenges. This project team was formed in June 2016 to collaborate with Subject Matter Experts (SMEs) from the industry, CDISC, and the FDA. The goal of this project team is to:

      1. Collect frequently asked questions (FAQs) from Industry. If you have a question for the team, email workinggroups@phuse.global.

      2. Assess the appropriateness of a question, develop & review a response, collaborate with CDISC/FDA for clarity if required.

      3. Publish the FAQ and responses on Advance Hub database for helpful implementation/strategy information.

      Project LeadsEmail
      Aatiya Zaidi, Gileadaatiya.zaidi@gilead.com
      Michael Wise, Edwards

      Michael_Wise@edwards.com

      Nicola Newton, PHUSE Project Coordinator

      nicky@phuse.global

      CURRENT STATUS (Updated Quarterly) 

      • Published more FAQs
      • Continue to address questions in key areas​
      Objectives & Deliverables Timelines 

      Publish responses to questions received under: 

      • Data Submission
      • SDTM/ADaM Harmonisation 
      • SDTM/ADaM IG Nuances 
      • Trial Design Domain 
      • Validation/Conformance Rules 
      Ongoing 
      Published DeliverablesDate
      Integration Strategies in Support of ISS/ISE Submissions: Version 1.027-Oct-2020
      Best Practices for Submissions of Event Adjudication: Version 1.002-Dec-2019
      , multiple selections available,
      {"serverDuration": 9, "requestCorrelationId": "895a1737c5184c1a85091e432f2508f4"}